Navigation Links
Nuvo Announces 2009 second quarter financial results
Date:8/7/2009

MISSISSAUGA, ON, Aug. 7 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, today announced its financial and operational results for the quarter ended June 30, 2009.

    Recent Corporate Developments:

    -   Received correspondence from U.S. Food and Drug Administration
        ("FDA") on August 4, 2009 advising that it was extending the
        Prescription Drug User Fee Act date ("PDUFA date") for Pennsaid
        approval to November 4, 2009;

    -   Entered into a license and development agreement with Mallinckrodt
        Inc., a subsidiary of Covidien (NYSE: COV), a leading global provider
        of healthcare products, granting it exclusive rights to market and
        sell Pennsaid(R), and its follow-on product, Pennsaid Plus(R), in the
        United States;

    -   Pennsaid Phase 3 study results were published in June 2009 edition of
        PAIN, the world's leading publication on pain research and
        treatments, and the official journal of the International Association
        for the Study of Pain; and,

    -   Nuvo had $26.3 million in cash and cash equivalents at June 30, 2009
        following receipt of the US$10 million upfront payment received from
        Covidien respecting its U.S. license of Pennsaid and Pennsaid Plus.
        Subsequent to the quarter end, Nuvo received additional proceeds of
        $5.7 million from the exercise of warrants that otherwise would have
        expired on July 13, 2009.

"While a decision from the FDA on our submission for Pennsaid has been delayed, we remain optimistic that Pennsaid will ultimately be approved for marketing in the United States," said Henrich Guntermann, President and Chief Executive Officer of Nuvo Research. "We believe that once Pennsaid is approved by the FDA, our marketing partner Covidien will help Pennsaid become a best-in-class treatment for knee osteoarthritis in a rapidly expanding U.S. market."

    Financial Results:
    (thousands of Canadian dollars)

                                      Three      Three        Six        Six
                                     months     months     months     months
                                      ended      ended      ended      ended
                                    June 30,   June 30,   June 30,   June 30,
                                       2009       2008       2009       2008
    -------------------------------------------------------------------------
    Revenue                        $  2,706   $  2,085   $  5,753   $  4,321
    Net loss                       $ (1,664)  $ (2,864)  $ (4,532)  $ (5,135)
    -------------------------------------------------------------------------

Revenue, consisting of product sales, license fee revenue, and research and other contract revenue, for the three months ended June 30, 2009 increased 30% to $2.7 million compared with $2.1 million for the three months ended June 30, 2008. The increase was attributable to a $0.4 million increase in Pennsaid product sales, the recognition of additional licensing fee revenue and research revenue earned on a collaboration agreement with a Fortune Global 500 company that develops and markets skin care products. Revenue for the six months ended June 30, 2009 increased 33% to $5.8 million compared to $4.3 million for the six months ended June 30, 2008. This increase is attributable to a $0.7 million increase in Pennsaid sales to our Canadian licensee and Greek distributor, the recognition of additional licensing fee revenue and higher research revenue.

Gross margin on product sales declined slightly to $0.6 million for the three months ended June 30, 2009 compared to $0.8 million for the comparable quarter in 2008. The decrease in gross margin is primarily attributable to the planned 8 week shutdown of the Pennsaid manufacturing facility to prepare for the U.S. launch of Pennsaid. For the six months ended June 30, 2009, gross margin on product sales grew to $1.9 million from $1.7 million in the six months ended June 30, 2008. The increase is due to higher Pennsaid sales, offset partially by higher material costs and incremental costs related to the planned shutdown.

Total operating expenses, excluding foreign currency gains and losses, for the three-month period ended June 30, 2009 decreased to $3.1 million compared to $3.9 million for the three months ended June 30, 2008. The decrease relates primarily to lower research and development expenses as Covidien reimbursed the Company $0.9 million for Pennsaid and Pennsaid Plus development costs incurred prior to signing the license agreement as per its terms. Offsetting these savings were higher SG A costs related to the US partnering activities that culminated in the signing of the licensing agreement with Covidien. For the six months ended June 30, 2009 total operating expenses, excluding foreign currency gains increased to $7.9 million compared to $7.6 million. The increase from 2008 relates to higher SG A costs and net interest expense, offset partially by lower research and development costs.

Research and development expenses were $0.8 million and $3.8 for the three and six months ended June 30, 2009, decreases of 61% and 11% compared with $2.1 million and $4.2 million for the three and six months ended June 30, 2008. The majority of the significant decrease in the quarter was due to a $0.9 million reimbursement received from Covidien for specific research and development costs incurred by Nuvo prior to signing the licensing agreement. In addition, under the terms of the licensing agreement, Covidien assumed responsibility for all Pennsaid and Pennsaid Plus development activities and costs subsequent to June 15, 2009. The Company also incurred expenditures for preclinical development of the Company's early stage pipeline candidates and costs relating to the expanded research and formulation development activities in San Diego.

SG A expenses increased to $1.8 million and $3.2 million for the three and six months ended June 30, 2009, compared to $1.2 million and $2.3 million for the three and six months ended June 30, 2008. The increase in both periods is primarily attributable to costs relating to US partnering activities that culminated in the signing of the licensing agreement with Covidien and the issuance and revaluation of units in the Company's Deferred Share Unit Plan ("DSU Plan") to their market value.

For the three months ended June 30, 2009, the Company's net loss declined significantly to $1.7 million compared to $2.9 million for the three months ended June 30, 2008. The Company was able to reduce its net loss as lower research and development costs, an increase in licensing fee revenue and a foreign exchange gain more than exceeded increases in SG A costs, higher net interest expense and the lower gross margin on product sales. For the six months ended June 30, 2009, net loss declined by 12% to $4.5 million from $5.1 million.

Cash and cash equivalents increased substantially to $26.3 million as at June 30, 2009 compared to $15.2 million as at December 31, 2008 and $14.2 million at March 31, 2009 primarily as a result of the $US10 million Upfront Payment received from Covidien and proceeds from the exercise of warrants.

Cash used in operations improved to $1.9 million for the quarter ended June 30, 2009 compared to $2.6 million for the quarter ended June 30, 2008. This was primarily attributable to the significantly lower net loss in the quarter. For the six-month period cash used in operations improved slightly to $4.8 million versus $4.9 million as the reduction in the net loss was primarily attributable to changes in items not involving current cash flows.

Net cash used in investing activities totaled $148,000 and $203,000 for the three and six months ended June 30, 2009 compared $57,000 and $56,000 in the three and six months ended June 30, 2008. The additions in the three and six months ended June 30, 2009 primarily relate to deposits on and purchases of new production equipment as the Company continued the process of expanding capacity at its Quebec manufacturing facility in preparation for the anticipated production launch of Pennsaid for the U.S. later this year.

Net cash provided by financing activities totaled $3.2 million and $5.3 million for the three and six months ended June 30, 2009, compared to $0.9 million for both the three and six months ended June 30, 2008. During the quarter, the Company received proceeds of $3.2 million ($5.4 million for the six months) upon the exercise of warrants including net proceeds of $1.5 million ($3.7 million for the six months) from the 2009 Warrant Incentive Program. In addition, subsequent to quarter end, the Company received additional proceeds of $5.7 million from the exercise of 19.1 million warrants prior to their expiry on July 13, 2009.

Detailed financial statements and the MD A are available at www.nuvoresearch.com or www.sedar.com.

About Pennsaid

Pennsaid, the Company's lead product, is used to treat the pain and symptoms associated with knee osteoarthritis. Pennsaid combines a transdermal carrier (containing dimethyl sulfoxide, popularly known as "DMSO") with diclofenac sodium, a leading non-steroidal anti-inflammatory drug ("NSAID"), and delivers the active drug through the skin directly to the site of pain. While, conventional oral NSAIDs expose patients to potentially serious systemic side effects such as gastrointestinal bleeding and cardiovascular risks, Nuvo's clinical trials suggest that some of these systemic side effects occur less frequently with topically applied Pennsaid. There are more than 27 million Americans suffering from osteoarthritis and the United States market for this condition is estimated at US$4 billion annually.

About Nuvo Research Inc.

Nuvo is focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies. Nuvo's lead product is Pennsaid, a topical NSAID used for the treatment of osteoarthritis of the knee. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of topical and transdermal products targeting a variety of indications.

Nuvo is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany and a research and development center in San Diego, California. For more information, please visit www.nuvoresearch.com.

These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report, as well as in the Company's Annual Information Form for the year ended December 31, 2008. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether a result of new information or future events, except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly filings, annual report and Annual Information Form and other filings found on SEDAR at www.sedar.com.

Summary financial statements attached:

                             NUVO RESEARCH INC.
                         CONSOLIDATED BALANCE SHEETS

                                                         As at         As at
                                                       June 30,  December 31,
                                                          2009          2008
                                                     Unaudited       Audited
    (thousands of Canadian dollars)                          $             $
    -------------------------------------------------------------------------
    ASSETS
    CURRENT
    Cash and cash equivalents                           26,260        15,219
    Accounts receivable                                  2,277         2,294
    Other receivable                                       367             -
    Inventories                                          1,724         1,393
    Prepaid expenses and other                             432           446
    -------------------------------------------------------------------------
    TOTAL CURRENT ASSETS                                31,060        19,352

    Restricted cash                                         89            93
    Property, plant and equipment                        1,896         1,990
    -------------------------------------------------------------------------
    TOTAL ASSETS                                        33,045        21,435
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    LIABILITIES AND SHAREHOLDERS' EQUITY
    CURRENT
    Accounts payable and accrued liabilities             2,400         2,736
    Deferred revenue                                     2,241         2,241
    Current portion of long-term debt and
     capital lease obligations                             162           181
    -------------------------------------------------------------------------
    TOTAL CURRENT LIABILITIES                            4,803         5,158
    Deferred revenue                                    13,542         3,321
    Long-term debt and capital lease obligations           227          320
    Debentures                                           2,795         4,774
    -------------------------------------------------------------------------
    TOTAL LIABILITIES                                   21,367        13,573
    -------------------------------------------------------------------------

    SHAREHOLDERS' EQUITY
    Common shares                                      202,524       189,603
    Warrants                                             6,466        10,847
    Contributed surplus                                  7,402         6,890
    Accumulated other comprehensive income                 114           114
    Deficit                                           (204,828)     (199,592)
    -------------------------------------------------------------------------
    TOTAL SHAREHOLDERS' EQUITY                          11,678         7,862
    -------------------------------------------------------------------------
    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY          33,045        21,435
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



                             NUVO RESEARCH INC.
           CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS

                                        Three-months           Six-months
    Unaudited                              ended                 ended
    (thousands of Canadian          June 30,   June 30,   June 30,   June 30,
     dollars except per share          2009       2008       2009       2008
     and share amounts)                   $          $          $          $
    -------------------------------------------------------------------------
    REVENUE
    Product sales                     2,075      1,795      4,458      3,770
    Cost of goods sold                1,449      1,001      2,583      2,085
    -------------------------------------------------------------------------
    Gross margin on product sales       626        794      1,875      1,685

    Other revenue
    Licensing fees                      560        250      1,120        500
    Research and other contract
     revenue                             71         40        175         51
    -------------------------------------------------------------------------
                                      1,257      1,084      3,170      2,236
    -------------------------------------------------------------------------

    EXPENSES
    Research and development            842      2,133      3,776      4,237
    Selling, general and
     administrative expenses          1,791      1,162      3,154      2,286
    Stock-based compensation            132        216        264        366
    Amortization of property,
     plant, and equipment and
     intangibles                        148        207        297        412
    Foreign currency (gain) loss       (210)        36       (219)      (243)
    Interest expense                    227        325        473        628
    Interest income                      (9)      (131)       (43)      (315)
    -------------------------------------------------------------------------
                                      2,921      3,948      7,702      7,371
    -------------------------------------------------------------------------
    Net Loss and total
     comprehensive loss              (1,664)    (2,864)    (4,532)    (5,135)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Net loss per common share -
     basic and diluted                (0.01)     (0.01)     (0.01)     (0.02)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Average number of common shares
     outstanding - basic and
     diluted (millions)               352.6      303.1      336.2      301.3
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



                             NUVO RESEARCH INC.
                    CONSOLIDATED STATEMENTS OF CASH FLOWS

                                        Three-months           Six-months
                                           ended                 ended
                                    June 30,   June 30,   June 30,   June 30,
    Unaudited                          2009       2008       2009       2008
    (thousands of Canadian dollars)       $          $          $          $
    -------------------------------------------------------------------------
    OPERATING ACTIVITIES
    Net loss                         (1,664)    (2,864)    (4,532)    (5,135)
    Items not involving current
     cash flows:
      Amortization                      148        207        297        412
      Deferred revenue recognized      (560)      (450)    (1,120)      (711)
      Stock-based compensation
       and payments                     132        216        264        366
      Deferred stock unit expense       145          -        239          -
      Accretion of interest on
       debentures                       147        227        295        434
      Other                            (273)        91       (257)      (261)
    Net change in non-cash
     working capital                   (276)       284       (576)      (342)
    Proceeds from licensing
     arrangements and advances
     on research contracts           11,318          -     11,341          -
    -------------------------------------------------------------------------
    CASH PROVIDED BY (USED IN)
     OPERATING ACTIVITIES             9,117     (2,289)     5,951     (5,237)
    -------------------------------------------------------------------------
    INVESTING ACTIVITIES
    Acquisition of property,
     plant and equipment               (148)       (57)      (203)       (84)
    Proceeds from sale of assets          -          -          -         28
    -------------------------------------------------------------------------
    CASH USED IN INVESTING ACTIVITIES  (148)       (57)      (203)       (56)
    -------------------------------------------------------------------------
    FINANCING ACTIVITIES
    Issuance of common shares and
     warrants, net of related costs   3,246        947      5,442        947
    Repayments of long-term debt
     and capital lease obligations      (32)       (16)       (94)       (60)
    -------------------------------------------------------------------------
    CASH PROVIDED BY
     FINANCING ACTIVITIES             3,214        931      5,348        887
    -------------------------------------------------------------------------
    Effect of exchange rate changes
     on cash and cash equivalents       (99)      (298)       (55)       (37)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Net change in cash and cash
     equivalents during the period   12,084     (1,713)    11,041     (4,443)
    Cash and cash equivalents,
     beginning of period             14,176     19,061     15,219     21,791
    -------------------------------------------------------------------------
    CASH AND CASH EQUIVALENTS,
     END OF PERIOD                   26,260     17,348     26,260     17,348
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Interest paid                       166        128        261        154
    -------------------------------------------------------------------------


'/>"/>
SOURCE Nuvo Research Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. GeoVax Labs, Inc. Announces Six Month 2009 Financial Results and Provides Operational Update
2. NATB Announces Partnership With Ronald McDonald House Charities(R)
3. LCA Announces More Requests for Bids on Lung Cancer Research Programs Funded Through the Department of Defense
4. ThermoGenesis Announces Launch of Res-Q System; New Device Expands Companys Presence in Bone Marrow Sector
5. Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results
6. AMN Healthcare Announces Second Quarter 2009 Results
7. IRIDEX Announces Second Quarter 2009 Conference Call and Release Date
8. NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions
9. ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program
10. Feline Pine Announces National Take Your Cat to the Vet Day August 22
11. MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology: